Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px
Document › Details

Molzym GmbH & Co. KG. (3/17/11). "Press Release: Seegene and Molzym Partner on Automated Molecular Sepsis Diagnostics. Worldwide First Automated Multiplex Real-time PCR Test Simultaneously Screens for Bacteria and Fungi and Antibiotic Resistances within

Organisations Organisation Molzym GmbH & Co. KG
  Group Kompass (Group)
  Organisation 2 Seegene Inc.
  Group Seegene (Group)
Products Product MolYsis sample preparation kit
  Product 2 Arrow DNA isolation device
Index term Index term Seegene–Kompass: MolYsis technology, 201103– collab Seegene Magicplex Sepsis test is based on Molzym MolYsis and Nordiag's Arrow system
Persons Person Chun, Jong-Yoon (Seegene 200705 CEO + founder)
  Person 2 Lorenz, Michael (Univ Bremen + Molzym)

Seegene and Molzym today announced a partnership on the automated Magicplex™ Sepsis, a new multi-pathogen screening test capable of quick and accurate identification of over 90 leading sepsis-causing pathogens. Magicplex Sepsis provides a novel and fast-acting diagnostic technique for hospitals to simultaneously verify a complex range of targets that indicate sepsis, the leading cause of death in non-coronary intensive care units worldwide. Seegene's automated Magicplex Sepsis will be introduced May 7th at the 2011 Congress of the European Society of Clinical Microbiology and Infectious Diseases (ECCMID) in Milan, Italy.

Sepsis is a deadly disease that leaves no clear track back to initial indications, which could include gram-positive bacteria, gram-negative bacteria or fungi. The results are devastating: the annual incidence rate of sepsis has increased 91.3 percent over the last 10 years, and every hour 25 people in the United States die from severe sepsis. One of every three patients who develop severe sepsis will die within a month. Severe sepsis, the leading cause of death in the non-coronary intensive care unit, takes more lives than breast, colorectal, pancreatic, and prostate cancers combined.

The Magicplex Sepsis Test simultaneously screens for over 90 sepsis-causing pathogens: 73 Gram (+), 12 Gram (-), 6 fungi, and 3 antibiotic resistant genes can also be discriminated. The Magicplex Sepsis Test requires 1ml of patient's whole blood and provides test results within three hours (after extraction). The microbial DNA enrichment is based on Molzym’s MolYsis technology enabling up to 40,000-fold DNA enrichment over conventional technologies. Automated DNA isolation is performed with Seegene’s Seeprep12 instrument based on Nordiag’s “Arrow” technology/system.

"The Magicplex Sepsis Test will be the new gold standard for performing accurate, rapid and cost-effective sepsis diagnosis," said Dr. Jong-Yoon Chun, chief executive officer of Seegene. "In treating sepsis, time and accuracy are demanded. Every hour of delay in giving patients the correct antibiotics results in an 8% increase in the mortality rate."

“The automation reduces the total process costs significantly and makes Magicplex Sepsis Test the first true routine sepsis test worldwide” says Prof. Dr. Michael Lorenz, Chief Scientific Officer at Molzym. Magicplex Sepsis Test is based on Seegene's proprietary READ™ technology, which combines the advantages of multiplex Real-Time PCR system. The result is a molecular diagnostic test system that provides higher specificity and sensitivity over currently available PCR systems. Magicplex Sepsis Test will not be available in the USA until regulatory clearance.

About Seegene

Seegene, Inc. is the leading biotechnology company developing, manufacturing and marketing innovative molecular diagnostic products. The company's proprietary technologies in both PCR and Real-time PCR named ACP™, DPO™, and READ™, set a new solution for high-throughput and simultaneous multi-pathogen detection called "multiplex PCR." The novel Real-time PCR technology, READ™, overcomes the limitations of conventional Real-time PCR, providing dramatic improvement in sensitivity and specificity. Seegene holds three novel Molecular diagnostic platforms: Seeplex® system adapting DPO™ Technology, Anyplex™ and Magicplex™ systems that are Real-time PCR detection platforms adapting DPO™ and READ™ technologies. For more information please visit or call +82 2 2240 4022.

About Molzym:

Molzym, headquartered in Bremen, Germany, is a manufacturer of innovative products for molecular diagnostics. Molzym's diagnostic products focus on proprietary technologies for the selective isolation of pathogen DNA from various clinical specimens. The new automation platform, selectNA™, allows for up to 40,000-fold better PCR sensitivity as compared to conventional DNA isolation protocols. The system therefore enables culture-independent direct testing of blood and supports the universal detection of pathogens causing culture negative infections. For further information -

Press contact: Jan Detmers, Phone: +49 421-696162-0 E-mail:

Record changed: 2019-06-09


Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Kompass (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Made Without Love 650x80px

» top